Abstract
Kester et al. conducted a double-blind, randomized trial with 102 healthy adult volunteers assigned to receive either RTS, S/AS01B or RTS,S/AS02A vaccine at 0, 1, and 2 months, and another 36 volunteers who were enrolled as infectivity controls (no vaccine). Malaria challenge was introduced 2– 3 weeks following the vaccine series, and protected vaccinees were rechallenged 5 months later. A total of 52 volunteers were assigned to receive RTS,S/AS01B and 50 volunteers were assigned to receive RTS,S/AS02A. The investigators measured the following immune responses: circumsporozoite protein (CSP)-specific IgG titers, CSP-specific CD4 T cells expressing activation markers (IL-2, IFN-γ, TNF-α, or CD40L), and interferon (IFN)-γ production assayed by ex vivo enzyme-linked immunospots (ELISPOTs).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
